Sentynl Therapeutics Partners with myTomorrows to Expand Global Access to Rare Disease Treatments
核心洞察
Sentynl Therapeutics (搜索) has appointed myTomorrows (搜索) as the new global provider for its Managed Access Program, focusing on rare diseases including Hutchinson-Gilford Progeria Syndrome (搜索) and processing-deficient Progeroid Laminopathies (搜索).
The partnership aims to expand treatment access for patients with ultra-rare conditions that accelerate premature aging in children, addressing unmet medical needs through pre-approval treatment options.
myTomorrows (搜索)' platform has previously helped over 16,200 patients and 2,600 physicians across 320+ sites in more than 128 countries access innovative therapies.
Sentynl Therapeutics (搜索), Inc., a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd., has appointed myTomorrows (搜索) as the new global provider for its Managed Access Program (MAP). The partnership focuses on expanding access to innovative treatments for rare diseases, particularly Hutchinson-Gilford Progeria Syndrome (搜索) (HGPS) and processing-deficient Progeroid Laminopathies (搜索) (PDPL), ultra-rare conditions that accelerate the premature aging process in children.
Strategic Partnership for Rare Disease Access
The transition to myTomorrows (搜索)' patient-centric platform represents a significant step in Sentynl's commitment to providing patients with access to life-extending therapies. myTomorrows is a global health technology company that connects patients with serious diseases, whose medical needs cannot be met by available standard of care, with pre-approval treatment options such as clinical trials and MAPs.
"It is Sentynl's mission to ensure patients with rare diseases have access to life-extending therapies," said Matt Heck, President & Chief Executive Officer of Sentynl. "As part of our commitment to the space, we are constantly seeking new ways to evolve and enhance that access. We are confident that myTomorrows (搜索)' deep expertise and forward-thinking approach will successfully help to expand the reach of our MAP with the highest standards of service and compliance."
Global Reach and Technology Platform
myTomorrows (搜索) brings substantial experience to the partnership, having helped more than 16,200 patients and 2,600 physicians across 320+ sites in over 128 countries. The company has built proprietary technology that conducts comprehensive and accurate searches of clinical trials and Expanded Access Programs (EAPs) from global public registries, efficiently connecting patients, physicians, trial sites and BioPharma companies.
Michel van Harten, MD, CEO of myTomorrows (搜索), emphasized the partnership's potential impact: "myTomorrows is proud to support Sentynl in continuing to broaden the availability of treatment, ensuring that no patient is left behind due to geography or regulatory delays. With our expertise in global access solutions, regulatory diligence, and patient-centric services, we look forward to scaling access to Sentynl's program."
Future Collaboration Opportunities
The companies plan to strengthen their collaboration across additional managed access programs, leveraging myTomorrows (搜索)' expertise in facilitating global access to treatments for a wide range of rare and ultra-rare diseases. This partnership underscores both companies' shared vision that patients worldwide should have facilitated access to innovative therapies they need.
Sentynl Therapeutics (搜索), acquired by the Zydus Group (搜索) in 2017, focuses on bringing innovative therapies to patients living with rare diseases. The company's experienced management team has previously built multiple successful pharmaceutical companies, with a focus on commercialization and sourcing effective, well-differentiated products across therapeutic areas to address unmet needs.